stoxline Quote Chart Rank Option Currency Glossary
  
Iterum Therapeutics plc (ITRM)
1  -0.13 (-11.5%)    07-14 16:00
Open: 1.12
High: 1.13
Volume: 925,343
  
Pre. Close: 1.13
Low: 1
Market Cap: 40(M)
Technical analysis
2025-07-14 4:41:14 PM
Short term     
Mid term     
Targets 6-month :  1.33 1-year :  1.49
Resists First :  1.13 Second :  1.27
Pivot price 1
Supports First :  0.91 Second :  0.75
MAs MA(5) :  1.04 MA(20) :  0.99
MA(100) :  1.13 MA(250) :  1.3
MACD MACD :  0 Signal :  -0.1
%K %D K(14,3) :  59.3 D(3) :  69.8
RSI RSI(14): 49.3
52-week High :  3.01 Low :  0.8
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ITRM ] has closed above bottom band by 49.5%. Bollinger Bands are 11.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.13 - 1.14 1.14 - 1.14
Low: 0.99 - 0.99 0.99 - 1
Close: 0.99 - 1 1 - 1.01
Company Description

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Headline News

Wed, 02 Jul 2025
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛

Wed, 02 Jul 2025
Iterum Therapeutics Strengthens Leadership Team: New CCO to Drive Next-Gen Antibiotics Commercialization - Stock Titan

Sun, 29 Jun 2025
Certain Options of Iterum Therapeutics plc are subject to a Lock-Up Agreement Ending on 30-JUN-2025. - MarketScreener

Wed, 25 Jun 2025
Iterum Therapeutics (ITRM) Releases Positive Phase 3 Trial Resul - GuruFocus

Mon, 16 Jun 2025
Transcript : Iterum Therapeutics plc - Special Call - MarketScreener

Wed, 11 Jun 2025
Iterum Therapeutics Inks Partnership With EVERSANA For Commercialization Of ORLYNVAH In US - Nasdaq

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 40 (M)
Shares Float 39 (M)
Held by Insiders 1 (%)
Held by Institutions 6.4 (%)
Shares Short 1,170 (K)
Shares Short P.Month 1,290 (K)
Stock Financials
EPS -0.94
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.08
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -38.6 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) -0.02
Sales Per Share 0
EBITDA (p.s.) -0.4
Qtrly Earnings Growth 0 %
Operating Cash Flow -17 (M)
Levered Free Cash Flow -11 (M)
Stock Valuations
PE Ratio -1.07
PEG Ratio 0
Price to Book value -14.29
Price to Sales 0
Price to Cash Flow -2.39
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android